Entyvio (vedolizumab) typically takes 6 to 14 weeks to produce noticeable symptom improvement, depending on whether you’re treating ulcerative colitis or Crohn’s disease. It works slower than many other biologics because of its gut-targeted approach, and the FDA recommends discontinuing it if there’s no meaningful benefit by week 14. That said, many patients continue to see gradual improvement well beyond that initial window.
Timeline for Ulcerative Colitis
If you have ulcerative colitis, Entyvio tends to kick in faster than it does for Crohn’s. In clinical trials, 47% of patients on Entyvio showed a clinical response by week 6, compared to 26% on placebo. About 17% achieved full remission at that same time point, and 41% showed signs of mucosal healing, meaning the intestinal lining itself was starting to repair.
But week 6 is far from the finish line. Patients who continued Entyvio through week 52 showed higher rates of both clinical and endoscopic remission than they had at week 6. Average symptom scores kept declining all the way out to a year, which suggests the medication builds effectiveness over months. If you feel some improvement early on but aren’t where you want to be, that’s a common pattern rather than a sign the drug isn’t working.
Timeline for Crohn’s Disease
Crohn’s disease responds more slowly. At week 6, clinical trials showed no significant difference between Entyvio and placebo, which can be discouraging if you’re comparing notes with someone who has ulcerative colitis. The separation from placebo became clear around week 10, when 27% of patients on Entyvio achieved remission compared to 12% on placebo.
Full clinical remission for Crohn’s generally takes at least 10 to 14 weeks. In one study, the median time to clinical response was 19 weeks, and mucosal healing took a median of 22 weeks. These are longer waits than many patients expect, but they reflect the nature of the drug rather than a failure to respond. If your doctor keeps you on Entyvio past the early weeks despite modest improvement, this extended timeline is likely why.
Why Entyvio Takes Longer Than Other Biologics
Most other biologics for inflammatory bowel disease work by blocking a protein called TNF throughout the entire body. Entyvio takes a completely different approach. It blocks a specific molecule on immune cells that acts like a homing signal, directing those cells to travel from the bloodstream into the gut lining. By interrupting this “gut homing” process, Entyvio gradually reduces the number of inflammatory immune cells accumulating in your intestines.
This gut-selective mechanism is the reason for both the slower onset and the favorable safety profile. Because Entyvio doesn’t suppress your immune system broadly, it avoids some of the infection risks associated with other biologics. The tradeoff is patience: rather than quickly dampening inflammation everywhere, it slowly starves the gut of the immune cells driving the disease. Existing inflammatory cells in the gut wall need time to clear out even after new ones stop arriving.
How Treatment Is Structured
Entyvio starts with an induction phase of intravenous (IV) infusions at weeks 0 and 2. After that, you receive a third infusion at week 6. These first three doses are designed to build up drug levels in your system. If you respond to induction, your doctor will transition you to maintenance therapy, which is either continued IV infusions every 8 weeks or subcutaneous injections (108 mg every 2 weeks) that you can give yourself at home. You need at least two IV doses before switching to the at-home injections.
The week 14 checkpoint is important. The FDA’s prescribing guidance recommends discontinuing Entyvio if there’s no evidence of meaningful therapeutic benefit by that point. This doesn’t mean you need to be in full remission. It means your doctor should be seeing some measurable trend in the right direction, whether that’s reduced bleeding, fewer bowel movements, improved lab markers, or better endoscopic findings.
Prior Biologic Use Affects Response
Your treatment history plays a significant role in how quickly and how well Entyvio works. Patients who haven’t previously tried other biologics (sometimes called “biologic-naive”) consistently respond at higher rates than those who have already tried and failed a TNF-blocking drug. This pattern holds at both week 6 and week 52 for ulcerative colitis, and a similar trend appears in Crohn’s disease.
This doesn’t mean Entyvio can’t work if you’ve been on other biologics before. It means your expectations for the timeline and likelihood of response should be calibrated accordingly. If you’re coming to Entyvio after one or more other biologics didn’t work, the odds are lower but still meaningful, and your doctor may give the drug a longer runway before deciding it isn’t effective.
Long-Term Remission Rates
For patients who do respond, Entyvio’s long-term numbers are encouraging. At one year, 46% of ulcerative colitis patients on maintenance Entyvio were in clinical remission, compared to just 14% on placebo. Among patients who achieved remission early (by week 6), about 30% maintained that remission through week 52 on Entyvio, versus 12% on placebo.
That 30% durability figure for early responders might sound low, but it reflects the strict definition of sustained remission used in clinical trials. Many patients who technically fell out of “remission” by rigid scoring criteria still experienced meaningful improvement in their daily symptoms compared to baseline. The broader takeaway is that Entyvio’s benefits tend to grow and stabilize over time rather than peaking early and fading.
What to Expect While Waiting
The hardest part of starting Entyvio is often the waiting period. During the first several weeks, you may not feel any different, particularly if you have Crohn’s disease. Some patients notice subtle changes first: less urgency, slightly less blood in stool, or a gradual reduction in the number of daily bowel movements. Others experience improvement that feels more sudden, often somewhere between weeks 6 and 14.
Your doctor will likely keep you on any current medications (such as steroids or immunomodulators) during the induction phase to manage symptoms while Entyvio builds up. The goal is usually to taper those medications once Entyvio takes hold, but that process happens gradually. If you’re still on steroids at week 14, it doesn’t necessarily mean the drug has failed. Many patients need several additional months to fully transition to Entyvio as their primary therapy.